FI954252A - Luukasvutekijä - Google Patents
Luukasvutekijä Download PDFInfo
- Publication number
- FI954252A FI954252A FI954252A FI954252A FI954252A FI 954252 A FI954252 A FI 954252A FI 954252 A FI954252 A FI 954252A FI 954252 A FI954252 A FI 954252A FI 954252 A FI954252 A FI 954252A
- Authority
- FI
- Finland
- Prior art keywords
- gly
- polypeptide
- lys
- ala
- pro
- Prior art date
Links
- 230000008468 bone growth Effects 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 9
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 241000700159 Rattus Species 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 3
- PEZMQPADLFXCJJ-ZETCQYMHSA-N 2-[[2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]acetyl]amino]acetic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(O)=O PEZMQPADLFXCJJ-ZETCQYMHSA-N 0.000 abstract 2
- BEMGNWZECGIJOI-WDSKDSINSA-N Ala-Gly-Glu Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O BEMGNWZECGIJOI-WDSKDSINSA-N 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 abstract 2
- 108010043293 glycyl-prolyl-glycyl-glycine Proteins 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 abstract 1
- FUHFYEKSGWOWGZ-XHNCKOQMSA-N Asn-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O FUHFYEKSGWOWGZ-XHNCKOQMSA-N 0.000 abstract 1
- OGMDXNFGPOPZTK-GUBZILKMSA-N Asn-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N OGMDXNFGPOPZTK-GUBZILKMSA-N 0.000 abstract 1
- YXPNKXFOBHRUBL-BJDJZHNGSA-N Cys-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N YXPNKXFOBHRUBL-BJDJZHNGSA-N 0.000 abstract 1
- HMHRTKOWRUPPNU-RCOVLWMOSA-N Gly-Ile-Gly Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O HMHRTKOWRUPPNU-RCOVLWMOSA-N 0.000 abstract 1
- GLYJPWIRLBAIJH-UHFFFAOYSA-N Ile-Lys-Pro Natural products CCC(C)C(N)C(=O)NC(CCCCN)C(=O)N1CCCC1C(O)=O GLYJPWIRLBAIJH-UHFFFAOYSA-N 0.000 abstract 1
- PJYSOYLLTJKZHC-GUBZILKMSA-N Leu-Asp-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O PJYSOYLLTJKZHC-GUBZILKMSA-N 0.000 abstract 1
- NJMXCOOEFLMZSR-AVGNSLFASA-N Leu-Met-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O NJMXCOOEFLMZSR-AVGNSLFASA-N 0.000 abstract 1
- SWWCDAGDQHTKIE-RHYQMDGZSA-N Lys-Arg-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWWCDAGDQHTKIE-RHYQMDGZSA-N 0.000 abstract 1
- XOQMURBBIXRRCR-SRVKXCTJSA-N Lys-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XOQMURBBIXRRCR-SRVKXCTJSA-N 0.000 abstract 1
- OBZHNHBAAVEWKI-DCAQKATOSA-N Lys-Pro-Asn Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O OBZHNHBAAVEWKI-DCAQKATOSA-N 0.000 abstract 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 abstract 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 abstract 1
- XIULAFZYEKSGAJ-IXOXFDKPSA-N Thr-Leu-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XIULAFZYEKSGAJ-IXOXFDKPSA-N 0.000 abstract 1
- WFAUDCSNCWJJAA-KXNHARMFSA-N Thr-Lys-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(O)=O WFAUDCSNCWJJAA-KXNHARMFSA-N 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 231100000673 dose–response relationship Toxicity 0.000 abstract 1
- 230000001605 fetal effect Effects 0.000 abstract 1
- 108010015792 glycyllysine Proteins 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 239000002853 nucleic acid probe Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3138693A | 1993-03-12 | 1993-03-12 | |
| US12021793A | 1993-09-13 | 1993-09-13 | |
| PCT/CA1994/000144 WO1994020615A1 (en) | 1993-03-12 | 1994-03-14 | Bone stimulating factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI954252A0 FI954252A0 (fi) | 1995-09-11 |
| FI954252A true FI954252A (fi) | 1995-09-11 |
Family
ID=26707172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI954252A FI954252A (fi) | 1993-03-12 | 1995-09-11 | Luukasvutekijä |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0688360B1 (fi) |
| JP (1) | JP3733381B2 (fi) |
| KR (1) | KR960701201A (fi) |
| CN (1) | CN1119457A (fi) |
| AT (1) | ATE208818T1 (fi) |
| AU (1) | AU678441B2 (fi) |
| BR (1) | BR9406447A (fi) |
| CA (1) | CA2157901A1 (fi) |
| CZ (1) | CZ234295A3 (fi) |
| DE (1) | DE69429082T2 (fi) |
| ES (1) | ES2168295T3 (fi) |
| FI (1) | FI954252A (fi) |
| HU (1) | HUT73297A (fi) |
| IL (1) | IL108947A0 (fi) |
| NO (1) | NO953286L (fi) |
| NZ (1) | NZ262352A (fi) |
| PL (1) | PL182236B1 (fi) |
| TW (1) | TW385314B (fi) |
| WO (1) | WO1994020615A1 (fi) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786327A (en) | 1993-03-12 | 1998-07-28 | Gensci Regeneration Sciences Inc. | Bone stimulating factor, methods of isolating same, and methods of increasing bone growth comprising administering same |
| US5880094A (en) * | 1995-06-07 | 1999-03-09 | Osteopharm Limited | Polypeptides that stimulate bone growth |
| US6117839A (en) * | 1995-06-07 | 2000-09-12 | Gensci Regeneration Sciences, Inc. | Bone stimulating factor |
| US6352973B1 (en) | 1995-06-07 | 2002-03-05 | Osteopharm Inc. | Bone stimulating factor |
| US6693081B2 (en) | 1995-09-26 | 2004-02-17 | Osteopharm Inc. | Bone stimulating factor |
| AU725516B2 (en) | 1997-09-19 | 2000-10-12 | Metabolix, Inc. | Biological systems for manufacture of polyhydroxyalkanoate polymers containing 4-hydroxyacids |
| DE19906096A1 (de) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein mit einem Heparin-bindenden Epitop |
| WO2000075185A1 (en) * | 1999-06-02 | 2000-12-14 | Osteopharm Inc. | Bone stimulating factor |
| EP1212464B1 (en) | 1999-08-30 | 2006-02-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for osteoporosis |
| US6815421B1 (en) | 2001-03-22 | 2004-11-09 | Osteopharm Inc. | Polypeptides for use in ameliorating effects of aging in mammals |
| ATE490339T1 (de) | 2003-08-08 | 2010-12-15 | Interleukin Genetics Inc | Diagnostikum für osteoporose |
| DE602007008147D1 (de) * | 2006-12-21 | 2010-09-09 | Numat As | Konsensus-peptid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0128041A3 (en) * | 1983-06-06 | 1986-12-03 | David Jeston Baylink | Polypeptides exhibiting skeletal growth factor activity |
| CA2020729A1 (en) * | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Bone morphogenetic protein |
-
1994
- 1994-03-11 IL IL10894794A patent/IL108947A0/xx unknown
- 1994-03-14 CZ CZ952342A patent/CZ234295A3/cs unknown
- 1994-03-14 ES ES94908917T patent/ES2168295T3/es not_active Expired - Lifetime
- 1994-03-14 EP EP94908917A patent/EP0688360B1/en not_active Expired - Lifetime
- 1994-03-14 KR KR1019950703855A patent/KR960701201A/ko not_active Application Discontinuation
- 1994-03-14 CA CA002157901A patent/CA2157901A1/en not_active Abandoned
- 1994-03-14 HU HU9502659A patent/HUT73297A/hu unknown
- 1994-03-14 AU AU61797/94A patent/AU678441B2/en not_active Ceased
- 1994-03-14 AT AT94908917T patent/ATE208818T1/de not_active IP Right Cessation
- 1994-03-14 CN CN94191456A patent/CN1119457A/zh active Pending
- 1994-03-14 NZ NZ262352A patent/NZ262352A/en unknown
- 1994-03-14 JP JP51844794A patent/JP3733381B2/ja not_active Expired - Fee Related
- 1994-03-14 WO PCT/CA1994/000144 patent/WO1994020615A1/en not_active Application Discontinuation
- 1994-03-14 PL PL94310617A patent/PL182236B1/pl unknown
- 1994-03-14 BR BR9406447A patent/BR9406447A/pt not_active Application Discontinuation
- 1994-03-14 DE DE69429082T patent/DE69429082T2/de not_active Expired - Fee Related
- 1994-03-21 TW TW083102552A patent/TW385314B/zh not_active IP Right Cessation
-
1995
- 1995-08-22 NO NO953286A patent/NO953286L/no not_active Application Discontinuation
- 1995-09-11 FI FI954252A patent/FI954252A/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO953286D0 (no) | 1995-08-22 |
| JP3733381B2 (ja) | 2006-01-11 |
| IL108947A0 (en) | 1994-06-24 |
| TW385314B (en) | 2000-03-21 |
| EP0688360B1 (en) | 2001-11-14 |
| NZ262352A (en) | 1997-10-24 |
| ES2168295T3 (es) | 2002-06-16 |
| CN1119457A (zh) | 1996-03-27 |
| CA2157901A1 (en) | 1994-09-15 |
| AU678441B2 (en) | 1997-05-29 |
| CZ234295A3 (en) | 1996-04-17 |
| WO1994020615A1 (en) | 1994-09-15 |
| HUT73297A (en) | 1996-07-29 |
| AU6179794A (en) | 1994-09-26 |
| NO953286L (no) | 1995-10-25 |
| PL310617A1 (en) | 1995-12-27 |
| HU9502659D0 (en) | 1995-11-28 |
| FI954252A0 (fi) | 1995-09-11 |
| EP0688360A1 (en) | 1995-12-27 |
| JPH08508158A (ja) | 1996-09-03 |
| DE69429082T2 (de) | 2002-07-25 |
| ATE208818T1 (de) | 2001-11-15 |
| KR960701201A (ko) | 1996-02-24 |
| PL182236B1 (pl) | 2001-11-30 |
| BR9406447A (pt) | 1996-02-13 |
| DE69429082D1 (de) | 2001-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gregory et al. | The primary structure of human urogastrone | |
| Weber et al. | Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina | |
| EP1053255A4 (en) | THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS, AND USES THEREOF | |
| FI954252A (fi) | Luukasvutekijä | |
| CA2000893C (en) | Biologically active lipoprotein and its use | |
| EP1175909A3 (en) | Therapeutic methods and compositions based on serrate proteins and nucleic acids | |
| DE3486154D1 (de) | Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung. | |
| ATE386118T1 (de) | Cnp-gen und vorläuferprotein aus schwein | |
| RU93045577A (ru) | Слитные полипептиды | |
| AU5963290A (en) | Inhibition of the n-end rule pathway in living cells | |
| Gelher et al. | The sequence of an atriopeptigen: a precursor of the bioactive atrial peptides | |
| Gluschankof et al. | The somatostatin-28 convertase of rat brain cortex generates both somatostatin-14 and somatostatin-28 (1–12) | |
| Piétu et al. | Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries | |
| US5814610A (en) | Osteogenic growth oligopeptides and pharmaceutical compositions containing them | |
| GLANVILLE et al. | Pepsin fragments of human placental basement-membrane collagens showing interrupted triple-helical amino acid sequences | |
| STEWART et al. | Synthetic parathyroid hormone-like protein-(1–74): Biochemical and physiological characterization | |
| EP0292257A3 (en) | Peptides having anf activity | |
| CA2163212A1 (en) | Therapeutic compounds | |
| FERRARA et al. | β‐Endorphin: Interaction of synthetic analogs having different chain lengths with morphine and enkephalin receptors in rat brain membranes | |
| Berger et al. | Mass-spectrometric analysis of ADP-ribosylation factors from bovine brain: identification and evidence for homogeneous acylation with the C14: 0 fatty acid (myristate) | |
| FR2691153B1 (fr) | Dodecapeptides monomere et dimere, utilisation en tant qu'agents anti-megacaryocytaires. | |
| Monet et al. | In vitro relative biological activities of (1--34) N-terminal synthetic fragments of human parathyroid hormone in the human renal cortical adenylate cyclase assay | |
| JP2796835B2 (ja) | ヒトカルパスタチン様ポリペプチド | |
| Ganeshan et al. | Recognition of neuropeptides FMRFamide and LPLRFamide by chicken cerebellum avian pancreatic polypeptide binding sites | |
| Yoshida et al. | Revision of the Amino Acid Sequence of Ribonuclease F1 |